SCHEMBL6084199

SCHEMBL6084199

Cc1ccc2nc(-c3c[nH]nc3-c3cccc(NS(=O)(=O)c4ccccc4C)c3)oc2c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 8/20 0.54
PTPN1 P18031 8/20 0.54
PTPN5 P54829 8/20 0.54
HSPD1 P10809 2/20 0.51
HSPE1 P61604 2/20 0.51
MAPT P10636 9/20 0.46
TP53 P04637 8/20 0.46
LMNA P02545 5/20 0.46
POLB P06746 1/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CETP P11597 1/20 0.42
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
RCE1 Q9Y256 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085283 0.93 PTPN1 (0.61) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL6085199 0.92 PTPN1 (0.61) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL6202869 0.89 MAPT (0.58) PTPN2PTPN1PTPN5MAPTTP53
SCHEMBL6086345 0.89 MAPT (0.54) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL6084084 0.88 ALDH1A1 (0.52) PTPN2PTPN1PTPN5MAPTTP53
SCHEMBL6084988 0.86 ALDH1A1 (0.53) PTPN2PTPN1PTPN5MAPTTP53
SCHEMBL6084264 0.84 PTPN2 (0.66) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL6084209 0.83 PTPN2 (0.49) PTPN2PTPN1PTPN5MAPTTP53
SCHEMBL6085204 0.83 PTPN1 (0.61) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL6200297 0.82 PTPN1 (0.63) PTPN2PTPN1PTPN5HSPD1HSPE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 PTPN2 370/4885PTPN1 344/4885PTPN5 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.